October 22, 2020 –
This webinar is intended for patients with inoperable extrahepatic cholangiocarcinoma (CCA) who consider enrolment into a clinical trial.
All patients included into the RELEASE trial will receive the standard treatment of gemcitabine and cisplatin, and half of the patients will receive the experimental PCI treatment in addition. The goal of the PCI treatment is to shrink the tumour in the extrahepatic CCA by increasing the effect of gemcitabine.
Prof. Jörg Trojan from Goethe-University Medical Center, Frankfurt, Germany will during the webinar give an overview of the ongoing RELEASE trial and some background information about the PCI technology and past clinical experience.